Major League Baseball and the Major League Baseball Players Association released the annual public report from the Joint Drug Prevention and Treatment Program’s independent program administrator, Dr. Thomas M. Martin, on Friday.

The 2024 reporting period, which ranged from the start of last offseason through the end of this year’s postseason, produced two positive tests among players on 40-man rosters, both for performance-enhancing substances.

In all, 11,609 tests were conducted during the reporting period, the second most in the history of the program, averaging nearly 10 annual tests for every 40-man-roster player.

Tests included 9,455 urine samples that were analyzed for performance-enhancing substances, stimulants, DHEA, diuretics, masking agents and drugs of abuse, and 2,154 blood samples that were analyzed for the presence of human growth hormone.

Over the past two testing periods, there have been three positive tests among players on 40-man rosters.